Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET

Company Participants

Joshua Higa - VP, IR
Emil Kakkis - CEO and President
Erik Harris - CCO
Howard Horn - CFO
Eric Crombez - CMO

Conference Call Participants

Chris Raymond - Piper Sandler
Tazeen Ahmad - Bank of America
Malcolm Kuno - JPMorgan
Gena Wang - Barclays
Lydia Erdman - Goldman Sachs
Maury Raycroft - Jefferies
Mehdi Goudarzi - Truist Securities
Yaron Werber - TD Cowen
Yigal Nochomovitz - Citi
Thomas Yip - H.C. Wainwright
Jack Allen - Baird
Joe Schwartz - Leerink Partners
Michael Riad - Morgan Stanley
Kristen Kluska - Cantor Fitzgerald
Dae Gon Ha - Stifel

Operator

Good afternoon and welcome to the Ultragenyx Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. At the end of the prepared remarks, you will have opportunity to ask questions during the question-and-answer portion of the call.

It is now my pleasure to turn the call to Joshua Higa, Vice President of Investor Relations.

Joshua Higa

Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Howard Horn, Chief Financial Officer; and Eric Crombez, Chief Medical Officer.

I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings.

I'll now turn the call over to Emil.

Emil Kakkis

Thanks Josh and good afternoon everyone. This is a great time for Ultragenyx as we successfully completed development work across our late-stage programs and now are reaching the submission stage.

If we achieve our approval from regulatory authorities, we expect to build further revenue momentum on top of our existing growing commercial portfolio. We continue to see substantial year-over-year revenue growth as we expand geographic access and further reach more patients with our medicines.

This growth could further accelerate up to three near-term BLA submissions and approvals for our treatment for both Sanfilippo syndrome Type A and GSDIa and potentially for osteogenesis imperfecta.

These three late-stage clinical programs could be first-ever approved treatments with the potential to dramatically improve the lives of patients and their families. Doing three submissions within the same year or so is a special opportunity we've earned with our investment in development in these last years, and we understand the importance of these efforts for the patient community.